<DOC>
	<DOCNO>NCT00352300</DOCNO>
	<brief_summary>This phase I trial study side effect give carboplatin paclitaxel together pegfilgrastim treat patient stage III stage IV ovarian epithelial , fallopian tube , primary peritoneal , carcinosarcoma cancer . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving carboplatin paclitaxel together pegfilgrastim surgery may kill tumor cell remain surgery .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel , Pegfilgrastim Treating Patients With Stage III Stage IV Ovarian Epithelial , Fallopian Tube , Primary Peritoneal , Carcinosarcoma Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Establish feasibility adjuvant dose-dense carboplatin paclitaxel follow pegfilgrastim , term absence grade 3 4 nonhematologic toxicity without major dose delay additional hematological support ( e.g. , red blood cell platelet transfusion admission febrile neutropenia ) , patient stage III-IV ovarian epithelial , fallopian tube , primary peritoneal cancer , carcinosarcoma cancer . SECONDARY OBJECTIVES : I . Estimate percentage patient develop ≥ grade 2 peripheral neurotoxicity regimen . II . Estimate clinical response rate patient measurable disease treat regimen . III . Assess toxicity regimen . OUTLINE : This multicenter study . Patients receive carboplatin IV paclitaxel IV 3 hour day 1 . Patients also receive pegfilgrastim subcutaneously day 2 . Treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Diagnosis 1 follow : Primary peritoneal carcinoma Fallopian tube carcinoma Ovarian epithelial carcinoma Carcinosarcoma Stage III IV disease Previously untreated disease , except mandatory prior surgery No ovarian epithelial carcinoma low malignant potential ( i.e. , borderline carcinoma ) GOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN No peripheral neuropathy ( sensory motor ) ≥ grade 2 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 5 year except nonmelanoma skin cancer No septicemia , severe infection , acute hepatitis No prior radiotherapy chemotherapy No prior cancer treatment would contraindicate study treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>